Cambridge Journal Critique Exposes Flawed Assumptions in WHO-World Bank $31B Pandemic Preparedness ROI

A peer-reviewed perspective in the Cambridge journal Health Economics, Policy and Law challenges the return-on-investment calculations underpinning the WHO and World Bank's 2022 G20 report recommending $31.1 billion annually for pandemic prevention, preparedness, and response (PPPR), with $10.5 billion from foreign aid. The analysis by University of Leeds researchers highlights problematic assumptions, including 100% mitigation of economic impacts via rapid vaccines, undervaluation of comparator diseases like HIV, TB, and malaria, and failure to account for behavioral adaptations or collateral costs of interventions. These inflate projected benefits by orders of magnitude while diverting resources from foundational health determinants such as nutrition and sanitation. The critique aligns with broader concerns in REPPARE project reports from the same institution, which question the evidence base for escalating pandemic budgets amid competing global health priorities. Official WHO-World Bank estimates frame the investment as yielding over 1,000-fold returns in wealthy nations, yet the reassessment suggests opportunity costs that could harm equity in low- and middle-income countries already burdened by post-COVID debt. This debate intersects with ongoing negotiations on the WHO Pandemic Agreement and amended International Health Regulations, where financing mechanisms remain contentious. Related analyses in Globalization and Health further scrutinize innovative financing tools, underscoring risks of over-reliance on pharmaceutical-centric approaches over systemic resilience.